Lexicon's Sotagliflozin Improves Cardiac Function in Mouse Study of Hypertrophic Cardiomyopathy

• Lexicon Pharmaceuticals highlighted two published preclinical studies showing sotagliflozin’s favorable effects on cardiac function and blood clot formation.
• One study found improved heart structure and function in mice with hypertrophic cardiomyopathy, supporting further evaluation.
• The second showed reduced platelet activation and clot formation in human blood samples and animal models without impairing normal clotting, unlike empagliflozin.
• Sotagliflozin’s ongoing Phase 3 SONATA-HCM trial covers symptomatic obstructive and non-obstructive hypertrophic cardiomyopathy; topline results are expected in first-quarter 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210830PRIMZONEFULLFEED9850026) on October 21, 2026, and is solely responsible for the information contained therein.